Bristol’s Astral Systems Secures US$28.3M (€26M) Series A to Support Medical Isotope Commercialisation

Deal Summary

Astral Systems, a British deep‑tech firm developing multi‑state fusion reactors for medical isotope production, closed a US$28.3M (€26M) Series A round. The financing was led by Mercia Ventures with participation from Tees River, Daphni, Blast Club, Speedinvest and Playfair. The capital will be used to scale modular reactors and bring isotopes to market by early 2027.